N4 Pharma PLC Exercise of Warrants and Issue of Equity (2259W)
14 August 2020 - 3:22PM
UK Regulatory
TIDMN4P
RNS Number : 2259W
N4 Pharma PLC
14 August 2020
14 August 2020
N4 Pharma plc
("N4 Pharma" or the "Company")
Exercise of Warrants and Issue of Equity
N4 Pharma Plc (AIM: N4P), the specialist pharmaceutical company
developing Nuvec(R), a novel delivery system for cancer treatments
and vaccines, announces that it has received notification to
exercise warrants representing 112,500 ordinary shares of 0.4 pence
each ("Ordinary Shares") in the Company for total consideration of
GBP4,500.
Application has been made for the 112,500 new Ordinary Shares to
be admitted to trading on AIM ("Admission"), which is expected to
occur at 8.00 a.m. on or around 20 August 2020. The new Ordinary
Shares will rank pari passu with the existing Ordinary Shares. The
Company does not hold any Ordinary Shares in treasury.
Following Admission and for the purposes of the Disclosure
Guidance and Transparency Rules, the Company's total issued share
capital will consist of 152,306,287 Ordinary Shares. Shareholders
may use this figure as the denominator for the calculations by
which they will determine if they are required to notify their
interest in, or a change to their interest in, the issued share
capital of the Company.
Enquiries:
N4 Pharma plc
Nigel Theobald, CEO Via Scott PR
Luke Cairns, Executive Director
SP Angel Corporate Finance LLP Tel: +44(0)20 3470
0470
Nominated Adviser and Joint Broker
Matthew Johnson/Caroline Rowe (Corporate
Finance)
Vadim Alexandre/Abigail Wayne/Rob Rees
(Corporate Broking)
Turner Pope Investments (TPI) Limited Tel: +44(0)20 3657
0050
Joint Broker
Andy Thacker
Scott PR
Georgia Smith Tel: +44(0)1477 539
539
About N4 Pharma
N4 Pharma is a specialist pharmaceutical company developing a
novel delivery system for cancer and vaccine treatments using its
unique silica nanoparticle delivery system called Nuvec(R).
N4 Pharma's business model is to partner with companies
developing novel antigens for cancer and vaccine treatments to use
Nuvec(R) as the delivery vehicle to get their antigen into cells to
express the protein needed for the required immunity. As these
products progress through pre clinical and clinical programs, N4
Pharma will seek to receive up front payments, milestone payments
and ultimately royalty payments once products reach the market.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
IOEFLFLVTTISLII
(END) Dow Jones Newswires
August 14, 2020 09:22 ET (13:22 GMT)
N4 Pharma (LSE:N4P)
Historical Stock Chart
Von Jun 2024 bis Jul 2024
N4 Pharma (LSE:N4P)
Historical Stock Chart
Von Jul 2023 bis Jul 2024